PDS Biotechnology Corp Stockholders Equity

• PDS Biotechnology Corp showed a decrease of -2.1% in Stockholders Equity from 2025 to 2025.
• This data is from PDS Biotechnology Corp's annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2016 to 2025 (25 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2015: -$50.64 million | Q1 2016: $114.72 million | Q2 2016: $106.76 million | Q3 2016: $97.51 million | Q1 2017: $78.65 million | Q2 2017: $84.27 million | Q3 2017: $74.65 million | Q1 2018: -$284.4 thousand | Q2 2018: -$807.6 thousand | Q3 2018: -$1.08 million | Q1 2019: $24.45 million | Q2 2019: $20.61 million | Q3 2019: $15.58 million | Q1 2020: $19.89 million | Q2 2020: $17.01 million | Q3 2020: $31.02 million.
• Over the full 25 years of available data (2016 to 2025), PDS Biotechnology Corp's Stockholders Equity has declined by 89.6%.
• Historical annual values: Fiscal year 2025: $9.25 million | Fiscal year 2025: $9.45 million | Fiscal year 2025: $15.96 million | Fiscal year 2025: $22.36 million | Fiscal year 2024: $19.00 million | Fiscal year 2024: $22.00 million | Fiscal year 2024: $30.92 million | Fiscal year 2024: $37.18 million | Fiscal year 2023: $26.13 million | Fiscal year 2023: $24.48 million | Fiscal year 2023: $32.44 million | Fiscal year 2023: $41.01 million | Fiscal year 2022: $44.00 million | Fiscal year 2022: $47.06 million | Fiscal year 2022: $51.43 million | Fiscal year 2022: $55.87 million | Fiscal year 2021: $63.21 million | Fiscal year 2021: $67.86 million | Fiscal year 2021: $72.99 million | Fiscal year 2021: $24.37 million | Fiscal year 2020: $27.13 million | Fiscal year 2019: $11.70 million | Fiscal year 2018: -$2.07 million | Fiscal year 2017: -$609.5 thousand | Fiscal year 2016: $89.28 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026